RANBAXY ALLOCATED SITE FOR ITS GREENFIELD MANUFACTURING FACILITY IN MALAYSIA
AGREEMENT SIGNED WITH KULIM HI TECH PARK
Kuala Lumpur, Malaysia; Gurgaon, India: Ranbaxy Malaysia Sdn Bhd (RMSB) today announced that it has been allocated the site for setting up its Greenfield manufacturing facility in Malaysia. The company signed a 'letter of offer' agreement with Kulim Hi Tech Park (KHTP), a wholly owned state agency and industrial park that houses various other leading industries. KHTP is located at Kulim in the state of Kedah, Malaysia.
The agreement was signed by T. Jeyabalan Thangarajah, Managing Director of RMSB and Tuan Haji Muhammad Sobri, President , KHTP in the presence of representatives of the Ministry of Investment Development Authority (MIDA) and Arun Sawhney, CEO & Managing Director, Ranbaxy.
The Ranbaxy Greenfield facility will be built on an area of around 15 acres with an investment of around US$ 35 million providing employment to over 200 people. This will be Ranbaxy's second manufacturing plant in Malaysia. Last year in September, the Government of Malaysia gave an approval to RMSB for setting up a Greenfield manufacturing facility in Malaysia as an Entry Point Project (EPP).
Commenting on the signing ceremony, T. Jeyabalan said, "Ranbaxy established its foothold in Malaysia three decades back and since then has been offering high quality, affordable generic medicines to the Malaysian healthcare system. The new Greenfield facility reinforces our long term commitment. " He further added, "In addition to serving the local market, the new facility will also export products to the ASEAN markets, Middle East, Europe, Sri Lanka, China and other select nations."
The RMSB new facility would manufacture dosage forms including tablets and capsules primarily in the Cardiovascular, Anti Diabetic, Anti-infective and Gastrointestinal segments. Ranbaxy's total output in Malaysia will be increased from 1 Billion doses/annum to 3 Billion doses/annum when the new facility is fully operational.
In the 2012 Malaysian budget, the Government of Malaysia liberalised investments into the healthcare sector and encouraged foreign companies.
About Ranbaxy Malaysia Sdn Bhd
Ranbaxy Malaysia Sdn Bhd (RMSB) is a joint venture company of Ranbaxy Laboratories Limited, India and Malaysian shareholders. Established in 1982, RMSB is today one of the major generic companies in this market providing medicines in the Cardiovascular, CNS, Anti-infective, Gastroenterology and Anti-viral therapeutic segments. RMSB manufacturing facility in Sungai Petani, Kedah, Malaysia, was commissioned in 1987. RMSB employs over 300 employees in Malaysia.
About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.